甲地孕酮改善晚期恶性肿瘤患者生活质量的疗效观察

The effects of megestrolacetate on the improvement of quality of life in patients with advanced malignant neoplasms

目的探讨甲地孕酮(MA)对晚期恶性肿瘤患者生活质量的改善作用。方法将72例晚期恶性肿瘤患者随机分为治疗组37例(MA加支持治疗)和对照组35例(单纯支持治疗),观察两组食欲、体重、疼痛、KPS评分及生存期的变化。结果治疗组食欲改善29例(80.6%),体重增加19例(52.8%),疼痛减轻15例(41.7%),KPS评分增加21例(58.3%);对照组食欲改善8例(22.9%),体重增加4例(11.4%),疼痛减轻3例(8.6%),KPS评分增加5例(14.3%),两组间比较差异有统计学意义(P<0.005),治疗组生存期与对照组比较差异有统计学意义(P<0.05),未见明显毒副反应。结论MA能显著改善晚期恶性肿瘤患者生活质量及恶病质,并具有一定的抗癌痛和延长生存期作用,是晚期恶性肿瘤患者有效的辅助治疗药物。

Objective To investigate the effect of megestrolacetate （MA）in improving the quality of life in patients with advaneed malignant neoplasms. Methods Seventy-two patients with advanced malignant neoplasms were randomized into two groups, treatment group（37 patients） were treated with MA plus supportive care,control group（35 patients） were treated with supportive care only. The changes of appetite, weight, pain, KPS and overall survival were observed in each group. Results In the treatment group, 29 cases（80.6%） got appetite improving, 19 cases（52.8%） gained weight, 15 cases（41.7% ）got pain relief, 21 cases（58.3% ）got KPS score increasing; In the oontrol group, 8 cases （22.9%） got appetite improving, 4 cases（11. 4% ） gained weight,3 cases（8.6% ）got pain relief, 5 cases（14.3% ）got KPS score increasing. The differences in two groups were significant （P〈0.05）. There were no obvious toxicity . The overall survival in the treatment group was longer than that in the control group significantly （P 〈 0.05）. Conclusions Megestrolacetate can improve the quality of llfe and dyscrasia of patients with advanced malignant neoplasms, at the same time can relieve cancer pain, prolong survival in some extent. Megestrolacetate is an effective drug in adjuvant therapy for patients with advanced malignant neoplasm.